ING Group’s Abiomed Inc ABMD Stock Holding History

ING Group’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,374	Closed	-$340K	–	562
2022 Q2	$340K	Buy	+1,374	New	+$371K	﹤0.01%	511
2022 Q1	–	Sell	-5,939	Closed	-$2.13M	–	624
2021 Q4	$2.13M	Buy	5,939 +2,129	+56%	+$719K	0.02%	465
2021 Q3	$1.24M	Buy	3,810 +90	+2%	+$30.5K	0.02%	471
2021 Q2	$1.16M	Buy	+3,720	New	+$1.14M	0.02%	422
2021 Q1	–	Sell	-2,997	Closed	-$972K	–	564
2020 Q4	$972K	Buy	2,997 +2,000	+201%	+$553K	0.02%	396
2020 Q3	$276K	Buy	+997	New	+$287K	0.01%	413
2019 Q2	–	Sell	-6,715	Closed	-$1.92M	–	861
2019 Q1	$1.92M	Buy	6,715 +1,477	+28%	+$491K	0.04%	219
2018 Q4	$1.7M	Buy	+5,238	New	+$1.82M	0.04%	249
2018 Q3	–	Sell	-3,244	Closed	-$1.33M	–	884
2018 Q2	$1.33M	Buy	+3,244	New	+$1.18M	0.03%	271
2017 Q4	–	Sell	-1,509	Closed	-$254K	–	921
2017 Q3	$254K	Buy	+1,509	New	+$228K	﹤0.01%	749

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

ING Group's ABMD Position: Q3 2022 in Review

ING Group sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 1,374 shares — an estimated $340K sold.

ING Group first reported a position in ABMD in Q3 2017 and held it in 10 quarters. The position peaked at $2.13M in Q4 2021. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

ING Group reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
ING Group sold 1,374 Abiomed Inc shares in Q3 2022, an estimated $340K.
ING Group first reported a position in Abiomed Inc in Q3 2017 and held it in 10 quarters.
ING Group's Abiomed Inc position peaked at $2.13M in Q4 2021.
517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on ING Group's 13F filing for Q3 2022, filed 14 Nov 2022.